Repare Therapeutics Inc. (RPTX)

Market Cap	74.75M
Revenue (ttm)	250,000
Net Income (ttm)	-109.86M
Shares Out	42.96M
EPS (ttm)	-2.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,452
Open	1.730
Previous Close	1.740
Day's Range	1.710 - 1.780
52-Week Range	0.890 - 4.070
Beta	0.93
Analysts	Strong Buy
Price Target	4.50 (+158.62%)
Earnings Date	Nov 6, 2025

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 129
• Stock Exchange: NASDAQ
• Ticker Symbol: RPTX
• Website: https://www.reparerx.com

Financial Performance

In 2024, Repare Therapeutics's revenue was $53.48 million, an increase of 4.58% compared to the previous year's $51.13 million. Losses were -$84.69 million, -9.71% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for RPTX stock is "Strong Buy." The 12-month stock price target is $4.5, which is an increase of 158.62% from the latest price.

Price Target

$4.5

(158.62% upside)

Analyst Consensus: Strong Buy